BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2021
Bergen, Norway, 17 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the second quarter and first half of 2021. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CEST today, please see below for details. Operational Highlights – second quarter of 2021 (including post-period end) COVID-19 Update from Phase II trials assessing bemcentinib in hospitalised COVID-19 patients (April) · Data from